What 11 Analyst Ratings Have To Say About Amedisys
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 11 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. According to these analysts, Amedisys has an average price target of $98.82, a decrease of 1.74% from the previous average price target of $100.57. The majority of the analysts are indifferent about the stock with 9 out of 11 giving a neutral rating.
July 27, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have given a neutral rating to Amedisys (NASDAQ:AMED) stock with an average price target of $98.82, a decrease of 1.74% from the previous target.
The majority of the analysts are indifferent about the stock which indicates a neutral outlook. The decrease in the average price target could potentially indicate a lower expected return for investors. However, as the ratings are mostly neutral, the impact on the stock price in the short term is likely to be minimal.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100